– USA, CA – Applied Molecular Transport Inc. (Nasdaq: AMTI), a clinical-stage biopharmaceutical company, today announced the appointment of seasoned and accomplished industry veteran Dr. Holly Schachner (M.D.) to its Board of Directors.
“We are very excited to welcome Dr. Schachner to AMT’s Board of Directors,” said CEO and co-founder , Dr. Tahir Mahmood. “Holly’s extensive experience and expertise in late-stage global clinical development and medical affairs across a broad range of therapeutic areas, coupled with her strengths in organizational development, will be invaluable as AMT prepares for the next stage of growth.”
About Dr. Holly Schachner
Dr. Schachner currently serves as CMO of DoubleRainbow Biosciences, Inc. Before Double Rainbow, Dr. Schachner was SVP and therapeutic head of clinical science at MyoKardia, where she led a new therapeutic area focused on diastolic dysfunction, myocardial inflammation, and ischemia. Before joining MyoKardia, Dr. Schachner was CMO of specialty medicine at Allergan, where she led the transformation to a matrixed medical organization and developed innovative and global approaches to education and clinical trials. Dr. Schachner’s career includes leadership roles as North America medical head for the diabetes cardiovascular business unit at Sanofi, as well as serving simultaneously as U.S. medical chair. Earlier in her career, Dr. Schachner held medical leadership positions at Bayer Diabetes Care, Pfizer, Inc., and Columbia University.
Dr. Schachner added, “This is an exciting time to join the AMT Board of Directors. The company’s unique platform is opening new possibilities in mucosal immunology and a wide range of diseases with unmet need. I look forward to collaborating with the AMT executive leadership team and my fellow board members to further advance the company’s portfolio of potentially transformational oral biologic therapeutics.”
Dr. Schachner holds a B.S. in Psychology from the University of Michigan, an M.D. from Stony Brook School of Medicine, and completed a pediatric residency and pediatric endocrinology fellowship at the Mount Sinai Medical Center in New York.
About Applied Molecular Transport
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelial barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly oral forms that are designed to either target local intestinal tissue or enter the systemic circulation to precisely address the relevant biology of a disease.
AMT’s headquarters, internal GMP manufacturing, and lab facilities are located in South San Francisco, CA.
For more information: https://www.appliedmt.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
